Tuesday, 14 January 2014

BrainStorm receives US patent notice of allowance for its stem cell technology

BrainStorm Cell Therapeutics, a company developing adult stem cell technologies for neurodegenerative diseases, announced today that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.

This patent relates to the method of production of the company's proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. Pending approval from the FDA, the company is currently preparing for its upcoming multi-center Phase II trial in the U.S. with its proprietary NurOwn™ stem cell therapy, which was developed from this method.

"This U.S. patent allowance solidifies our intellectual property protection for our unique production method, as it reinforces the Notice recently received from the European Patent Office for the same technology, announced last week." said Mr. Chaim Lebovits, BrainStorm's President and Principal Executive Officer.

BrainStorm is the exclusive worldwide licensee of this technology from Ramot, the technology transfer company of Tel Aviv University, where it was developed by Professors Daniel Offen and Eldad Melamed.


No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !